Davis Timothy E JR
CIK: 0001492082
Associated companies
Transaction History
| SIBN | ▲ Buy | Grant | 10,957 | $0 | 6/4/2026 | View on chart |
| SIBN | ▼ Sell | Open Market | 3,500 | $49K | 5/29/2026 | View on chart |
| SIBN | ▲ Buy | Option Exercise | 12,064 | $52K | 5/28/2026 | View on chart |
| SIBN | ▼ Sell | Open Market | 3,780 | $55K | 5/28/2026 | View on chart |
| SIBN | ▲ Buy | Grant | 8,675 | $0 | 6/5/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,791 | $0 | 6/26/2024 | View on chart |
| SIBN | ▲ Buy | Option Exercise | 21,111 | $68K | 1/2/2024 | View on chart |
| SIBN | ▼ Sell | Open Market | 9,900 | $207K | 1/2/2024 | View on chart |
| SIBN | ▲ Buy | Grant | 4,866 | $0 | 6/9/2023 | View on chart |
| SIBN | ▲ Buy | Grant | 8,324 | $0 | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Truist Securities raises SI-BONE price target to $25
Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.
Truist Securities raises SI-BONE price target to $25. Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.